CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 47 enrolled
Drug / intervention
Lanraplenib +3 moredrug
Likely dose
Lanraplenib 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03134222
NCT03134222Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

Gilead Sciences·interventional·Posted Apr 28, 2017·Updated Jun 9, 2020

In Brief

A Phase 2 clinical trial evaluating Lanraplenib, Filgotinib, and 2 other interventions for Cutaneous Lupus Erythematosus. Completed, enrolled 47 participants across 16 sites in 2 countries.

Detailed Summary

The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib (formerly GS-9876) in females with moderately-to-severely active cutaneous lupus erythematosus (CLE).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCutaneous Lupus Erythematosus
CountriesCanada, United States
CollaboratorsLakefront Biotherapeutics NV

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedApr 28, 2017
Enrollment StartMay 24, 2017
Primary CompletionMar 13, 2019
Study CompletionDec 18, 2019
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 9.2 years ago

Interventions

Lanraplenibdrug

30 mg tablets administered orally once daily with or without food

Filgotinibdrug

200 mg tablets administered orally once daily with or without food

Lanraplenib placebodrug

Tablets administered orally once daily with or without food

Filgotinib placebodrug

Tablets administered orally once daily with or without food